依洛尤单抗联合阿托伐他汀钙治疗超高危急性冠状动脉综合征经皮冠状动脉介入术后患者的效果  

Effects of Evolocumab combined with Atorvastatin calcium in treatment of patients with ultra-high-risk acute coronary syndrome after percutaneous coronary intervention

作　　者：代锦文 周成[1] DAI Jinwen;ZHOU Cheng(Department of Western Medicine of Nanyang Central Hospital,Nanyang 473000 Henan,China)

机构地区：[1]南阳市中心医院西药科,河南南阳473000

出　　处：《中国民康医学》2024年第16期31-33,37,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察依洛尤单抗联合阿托伐他汀钙治疗超高危急性冠状动脉综合征经皮冠状动脉介入术(PCI)后患者的效果。方法:选取2022年6月至2023年6月该院收治的120例超高危急性冠状动脉综合征患者进行前瞻性研究,根据随机数字表法将其分为对照组和观察组各60例。两组均于PCI前后进行双联抗血小板药物治疗,在此基础上,对照组予以阿托伐他汀钙治疗,观察组在对照组基础上联合依洛尤单抗治疗,两组均连续治疗6个月。比较两组临床疗效,治疗前后血脂指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎性因子[高迁移率族蛋白B1(HMGB1)、淀粉样蛋白A1(SAA1)、CC趋化因子配体19(CCL19)]、血管内皮功能指标[一氧化氮(NO)、内皮素-1(ET-1)]水平,以及不良反应发生率。结果:观察组治疗总有效率为96.67%(58/60),高于对照组的78.33%(47/60),差异有统计学意义(P<0.05);治疗后,观察组LDL-C、TG、TC水平低于对照组,HDL-C水平高于对照组,差异均有统计学意义(P<0.05);治疗后,观察组SAA1、HMGB1、CCL19水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组NO水平高于对照组,ET-1水平低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:依洛尤单抗联合阿托伐他汀钙治疗超高危急性冠状动脉综合征PCI术后患者可提高治疗总有效率,改善血脂指标、血管内皮功能指标水平,降低炎性因子水平,效果优于单纯阿托伐他汀钙治疗。Objective:To observe effects of Evolocumab combined with Atorvastatin calcium in treatment of patients with ultra-high-risk acute coronary syndrome after percutaneous coronary intervention(PCI).Methods:A prospective study was conducted on 120 patients with ultra-high-risk acute coronary syndrome admitted to this hospital from June 2022 to June 2023.They were divided into control group and observation group according to the random number table method,60 cases in each group.Both groups were treated with dual antiplatelet drugs before and after PCI.On this basis,the control group was treated with Atorvastatin calcium,while the observation group was treated with Evolocumab on the basis of the control group.Both groups were treated continuously for 6 months.The clinical efficacy,the levels of blood lipid indexes[total cholesterol(TC),triacylglycerol(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],inflammatory factors[high mobility group protein B1(HMGB1),amyloid protein A1(SAA1),CC chemokine ligand 19(CCL19)]and vascular endothelial function indexes[nitric oxide(NO),endothelin-1(ET-1)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 96.67%(58/60),which was higher than 78.33%(47/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LDL-C,TG and TC in the observation group were lower than those in the control group,the level of HDL-C was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of SAA1,HMGB1 and CCL19 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of NO in the observation group was higher than that in the control group,the level of ET-1 was lower than that in the control group,and the differences w

关 键 词：超高危 急性冠状动脉综合征 经皮冠状动脉介入术 依洛尤单抗 阿托伐他汀钙 血脂 血管内皮功能 

分 类 号：R972.6[医药卫生—药品]